^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    U2AF1 mutation

    i
    Other names: U2AF1, U2 Small Nuclear RNA Auxiliary Factor 1, U2(RNU2) Small Nuclear RNA Auxiliary Factor Binding Protein, U2 SnRNP Auxiliary Factor Small Subunit, Splicing Factor U2AF 35 KDa Subunit, U2AFBP, U2AF35, U2 Small Nuclear Ribonucleoprotein Auxillary Factor, 35-KD Subunit, U2(RNU2) Small Nuclear RNA Auxiliary Factor 1, U2 Small Nuclear RNA Auxillary Factor 1, Splicing Factor U2AF 35kDa Subunit, U2 Auxiliary Factor 35 KDa Subunit, RNU2AF1, FP793, RN
    Entrez ID:
    7307
    Related biomarkers:
    Mutation
    10ms
    📍subgroup of MDS related gene mutations (ASXL1, SRSF2, SF3B1, STAG2, RUNX1, BCOR, EZH2, U2AF1 and ZRSR2) 👉🏻 OS: CPX-351 38.4 m vs Ida-FLAG 16.3 m #AML19 #AML19trial #MDS #AML @ASH_hematology @BloodAdvances @AML_Hub @jadothm (@DrJCornago)
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • STAG2 mutation
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1year
    Mnemonic for ICC AML with myelodysplasia-related gene mutations. ABUSERZ: A(ASXL1), B (BCOR), U(U2AF1), S (SF3B1, SRSF2, STAG2), E (EZH2), R (RUNX1), Z(ZRSR2). WHO classification lacks RUNX1. #hemepath #pathology #molpath @sanamloghavi @KMirza @Dr_AmerZeidan (@Dr_QayyumS)
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    U2AF1 mutation
    over1year
    U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes | Blood Advances | American Society of Hematology https://t.co/FQ6HhHUuSz (@syed_abutalibmd)
    U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    EZH2 mutation • U2AF1 mutation
    over1year
    #SUS_ZEBRAS 🦓 My mnemonic for #AML with #myelodysplasia_related_gene_mutations #STAG2 #U2AF1 #SF3B1 #ZRSR2 #EZH2 #BCOR #RUNX1 #ASXL1 #SRSF2 #AMLsm #MDSsm #WHO #myeloid_classification @AlkaliDr (@AlkaliDr)
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    U2AF1 mutation
    over1year
    U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes https://t.co/xBDsbbo1jD (@ZaidAR_MD)
    U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    EZH2 mutation • U2AF1 mutation
    over1year
    Moffitt research led by @Ramikomrokji published in @BloodAdvances finds U2AF1 & EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes. Read the full article here https://t.co/6FZnT4wOQM (@MoffittResearch)
    U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    EZH2 mutation • U2AF1 mutation
    over1year
    Our manuscript just published , kudos to my super fellow Dr luis Aguirre @LeafOnc helping me putting the story together. @md_padron @dana_rollison. U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes https://t.co/3w5RroVbps (@Ramikomrokji)
    U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    EZH2 mutation • U2AF1 mutation
    over2years
    $CRIS 40% CR/CRh rate in R/R AML patients with U2AF1 or SF3B1 spliceosome mutation treated with CA-4948 57% ORR observed in R/R MDS patients with U2AF1 or SF3B1 spliceosome mutation treated with CA-4948. CC at 8 a.m. ET (@BioStocks)
    Clinical
    |
    SF3B1 (Splicing Factor 3b Subunit 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    U2AF1 mutation
    |
    emavusertib (CA-4948)
    almost3years
    ▶️ https://t.co/kxVWAenS4v Is Secondary #AML Associated w/Specific Mutations❓ "...the presence of what we call spliceosome mutations, & SRSF2, SF3B1, U2AF1, & others can be specifically linked to a secondary #AML origin..."@EuniceWangMD #meded #SoMe #MedTwitter #CME #CPE (@MediComOncology)
    SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    SF3B1 mutation • SRSF2 mutation • U2AF1 mutation
    3years
    1/ Splicing mutations (SRSF2, U2AF1, SF3B1, ZRSR2) are common in sAML, and correspond to inferior outcomes when identified in de novo AML @BloodJournal @Haematologica https://t.co/9460cvp2yu https://t.co/aABTHuPY5P (@CLachowiez)
    SF3B1 (Splicing Factor 3b Subunit 1) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    SF3B1 mutation • SRSF2 mutation • U2AF1 mutation